The Chemokine CXCL16 Is a New Biomarker for Lymph Node Analysis of Colon Cancer Outcome.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ genetics
Caco-2 Cells
Cell Line, Tumor
Chemokine CXCL16
/ genetics
Chemokines, CXC
/ genetics
Colonic Neoplasms
/ genetics
Female
Gene Expression Regulation, Neoplastic
HT29 Cells
Humans
Lymph Nodes
/ metabolism
Male
Middle Aged
Prognosis
Survival Analysis
Up-Regulation
CEA
CXCL17
EpCAM
chemokines
immunohistochemistry
immunomorphometry
qRT-PCR
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
18 Nov 2019
18 Nov 2019
Historique:
received:
15
10
2019
revised:
07
11
2019
accepted:
13
11
2019
entrez:
23
11
2019
pubmed:
23
11
2019
medline:
9
4
2020
Statut:
epublish
Résumé
Chemokines are important in the development and progression of tumors. We investigated the expression of CXCL14 and CXCL16 in colon cancer. Expression of mRNA was assessed in primary tumors and lymph nodes and CXCL16 mRNA levels were correlated to patient's survival. Protein expression was investigated by two-color immunofluorescence and immunomorphometry. CXCL14 and CXCL16 mRNA levels and protein expression were significantly higher in colon cancer primary tumors compared to apparently normal colon tissue. Positive cells were tumor cells, as revealed by anti-CEA and anti-EpCAM staining. CXCL16, but not CXCL14, mRNA levels were significantly higher in hematoxylin and eosin positive (H&E(+)) compared to H&E(-) colon cancer lymph nodes or control nodes (
Identifiants
pubmed: 31752131
pii: ijms20225793
doi: 10.3390/ijms20225793
pmc: PMC6888697
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
CXCL14 protein, human
0
CXCL16 protein, human
0
Chemokine CXCL16
0
Chemokines, CXC
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Swedish Research Council-Medicine and Health
ID : 2011
Organisme : Lions Cancer Research Fund
ID : 2018
Références
Chin J Cancer Res. 2018 Dec;30(6):633-646
pubmed: 30700932
Blood. 2002 Jul 1;100(1):11-6
pubmed: 12070001
Cancer Immunol Res. 2014 Dec;2(12):1125-31
pubmed: 25480554
Mol Med Rep. 2014 Sep;10(3):1561-8
pubmed: 24938992
Clin Exp Immunol. 2008 Feb;151(2):326-33
pubmed: 18190460
Ann Surg Oncol. 2012 Jul;19 Suppl 3:S518-27
pubmed: 21845497
Cancer Res. 2007 May 15;67(10):4725-31
pubmed: 17510400
Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4903-8
pubmed: 12679517
Br J Cancer. 2016 Mar 15;114(6):697-703
pubmed: 26889977
Scand J Immunol. 2003 Dec;58(6):628-41
pubmed: 14636419
J Transl Med. 2013 Jan 07;11:6
pubmed: 23294544
Discov Med. 2013 Oct;16(88):137-47
pubmed: 24099668
Nat Immunol. 2000 Oct;1(4):298-304
pubmed: 11017100
Scand J Immunol. 2004 Jun;59(6):566-73
pubmed: 15182252
Tumour Biol. 2018 Sep;40(9):1010428318799251
pubmed: 30198422
J Immunol. 2004 Mar 15;172(6):3678-85
pubmed: 15004171
J Clin Invest. 2001 Mar;107(5):595-601
pubmed: 11238560